1. Home
  2. ARVN vs HDL Comparison

ARVN vs HDL Comparison

Compare ARVN & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.26

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$10.36

Market Cap

601.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
HDL
Founded
2015
2016
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
601.9M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
ARVN
HDL
Price
$7.26
$10.36
Analyst Decision
Buy
Buy
Analyst Count
16
3
Target Price
$13.93
★ $17.93
AVG Volume (30 Days)
★ 646.8K
1.6K
Earning Date
11-04-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 58.84
N/A
EPS
★ 1.70
N/A
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$12.76
$9.19
Revenue Next Year
N/A
$14.22
P/E Ratio
★ $4.54
$55.56
Revenue Growth
N/A
★ N/A
52 Week Low
$6.74
$9.74
52 Week High
$14.22
$18.33

Technical Indicators

Market Signals
Indicator
ARVN
HDL
Relative Strength Index (RSI) 43.63 37.49
Support Level $6.74 N/A
Resistance Level $7.74 $11.90
Average True Range (ATR) 0.36 0.24
MACD 0.08 -0.10
Stochastic Oscillator 51.43 28.66

Price Performance

Historical Comparison
ARVN
HDL

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

Share on Social Networks: